Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Widschwendter

Showing results (161-170 of 175) with videos related to

Pageof 18
Sort By:
Nature Aging|September 16, 2024
Challenges and recommendations for the translation of biomarkers of aging, Chiara M S Herzog, Ludger J E Goeminne, et al.
Lancet (London, England)|December 29, 2015
Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trialIan J Jacobs, Usha Menon, Andy Ryan, et al.
Gynecologic Oncology|November 11, 2022
Profiling the immune landscape in mucinous ovarian carcinomaNicola S Meagher, Phineas Hamilton, Katy Milne, et al.
BMC Genomics|June 20, 2014
Relationship between genome and epigenome--challenges and requirements for future researchGeneviève Almouzni, Lucia Altucci, Bruno Amati, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 25, 2021
Radiotherapy Versus Inguinofemoral Lymphadenectomy as Treatment for Vulvar Cancer Patients With Micrometastases in the Sentinel Node: Results of GROINSS-V IIMaaike H M Oonk, Brian Slomovitz, Peter J W Baldwin, et al.
The Journal of Pathology|December 13, 2021
Validated biomarker assays confirm that ARID1A loss is confounded with MMR deficiency, CD8<sup>+</sup> TIL infiltration, and provides no independent prognostic value in endometriosis-associated ovarian carcinomasKarolin Heinze, Tayyebeh M Nazeran, Sandra Lee, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|June 27, 2019
A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastasesNicola S Meagher, Linyuan Wang, Peter F Rambau, et al.
British Journal of Cancer|November 3, 2022
Increased FOXJ1 protein expression is associated with improved overall survival in high-grade serous ovarian carcinoma: an Ovarian Tumor Tissue Analysis Consortium StudyAshley Weir, Eun-Young Kang, Nicola S Meagher, et al.
Medrxiv : the Preprint Server for Health Sciences|November 21, 2023
Concurrent RB1 loss and <i>BRCA</i>-deficiency predicts enhanced immunological response and long-term survival in tubo-ovarian high-grade serous carcinomaFlurina A M Saner, Kazuaki Takahashi, Timothy Budden, et al.
The Journal of Pathology. Clinical Research|August 1, 2018
Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium studyPeter F Rambau, Robert A Vierkant, Maria P Intermaggio, et al.
Pageof 18

Showing results (161-170 of 175) with videos related to

Sort By:
Pageof 18
Nature Aging|September 16, 2024
Challenges and recommendations for the translation of biomarkers of aging, Chiara M S Herzog, Ludger J E Goeminne, et al.
Lancet (London, England)|December 29, 2015
Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trialIan J Jacobs, Usha Menon, Andy Ryan, et al.
Gynecologic Oncology|November 11, 2022
Profiling the immune landscape in mucinous ovarian carcinomaNicola S Meagher, Phineas Hamilton, Katy Milne, et al.
BMC Genomics|June 20, 2014
Relationship between genome and epigenome--challenges and requirements for future researchGeneviève Almouzni, Lucia Altucci, Bruno Amati, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 25, 2021
Radiotherapy Versus Inguinofemoral Lymphadenectomy as Treatment for Vulvar Cancer Patients With Micrometastases in the Sentinel Node: Results of GROINSS-V IIMaaike H M Oonk, Brian Slomovitz, Peter J W Baldwin, et al.
The Journal of Pathology|December 13, 2021
Validated biomarker assays confirm that ARID1A loss is confounded with MMR deficiency, CD8<sup>+</sup> TIL infiltration, and provides no independent prognostic value in endometriosis-associated ovarian carcinomasKarolin Heinze, Tayyebeh M Nazeran, Sandra Lee, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|June 27, 2019
A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastasesNicola S Meagher, Linyuan Wang, Peter F Rambau, et al.
British Journal of Cancer|November 3, 2022
Increased FOXJ1 protein expression is associated with improved overall survival in high-grade serous ovarian carcinoma: an Ovarian Tumor Tissue Analysis Consortium StudyAshley Weir, Eun-Young Kang, Nicola S Meagher, et al.
Medrxiv : the Preprint Server for Health Sciences|November 21, 2023
Concurrent RB1 loss and <i>BRCA</i>-deficiency predicts enhanced immunological response and long-term survival in tubo-ovarian high-grade serous carcinomaFlurina A M Saner, Kazuaki Takahashi, Timothy Budden, et al.
The Journal of Pathology. Clinical Research|August 1, 2018
Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium studyPeter F Rambau, Robert A Vierkant, Maria P Intermaggio, et al.
Pageof 18